Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors

Zhao, Qian and Manning, James and Sutton, James and Costales, Abran and Sendzik, Martin and Shafer, Cynthia and Levell, Julian and Liu, Gang and Caferro, Thomas and Cho, Young and Palermo, Mark and Chenail, Gregg and Dooley, Julie and Villalba, Brian and Farsidjani, Alireza and Chen, Jinyun and Dodd, Stephanie and Gould, Ty and Liang, Guiqing and Slocum, Kelly and Pu, Minying and Firestone, Brant and Growney, Joseph and Heimbach, Tycho and Pagliarini, Raymond (2018) Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors. ACS Medicinal Chemistry Letters, 9. pp. 746-751. ISSN 19485875

Abstract

Mutant isocitrate dehydrogenase 1 (IDH1) is an attractive therapeutic target for the treatment of various cancers such as AML, glioma and glioblastoma. We have evaluated 3-pyrimidin-4-yl-oxazolidin-2-ones as mutant IDH1 inhibitors that bind to an allosteric, induced pocket of IDH1R132H. This letter describes SAR exploration focused on improving both the in vitro and in vivo metabolic stability of the compounds, leading to the identification of 19 as a potent and selective mutant IDH1 inhibitor that has demonstrated brain penetration and excellent oral bioavailability in rodents. In a preclinical patient-derived IDH1 mutant xenograft tumor model study, 19 efficiently inhibited the production of the biomarker, 2-HG.

Item Type: Article
Date Deposited: 02 Aug 2018 00:45
Last Modified: 02 Aug 2018 00:45
URI: https://oak.novartis.com/id/eprint/36100

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.